In what represents its first patenting, Alva Health Inc. has been granted protection for a method for detecting stroke from falls using a combination of wearable motion sensors and artificial intelligence.
Richmond Hill, N.Y.-based Ihealthscreen Inc. reported the granting of a patent from the USPTO for automated systems for predicting and detecting the onset of glaucoma.
Carelight Ltd. reported seeking protection for a wearable real time opto-physiological monitoring system for monitoring heart rate, respiration rate, oxygen saturation, blood pressure, heart rate variability, pulse wave velocity, and body temperature.
Surgeon, CEO and founder of Hutom Corp., Woo Jin Hyung, is working to level the playing field in the operating room with artificial intelligence (AI) and big data, leveraging digital technology to optimize surgical outcomes.
The European Parliament (EP) has passed the Artificial Intelligence Act (AI Act), bringing the legislation one step closer to full passage into law, with passage by the European Council the only remaining hurdle.
The U.K. government said it will take action to tackle potential bias in the design and use of medical devices after an independent review found that there is extensive evidence of poorer performance of certain technologies, like pulse oximeters, in patients with darker skin tones.
Researchers from the University of Edinburgh seek protection for an algorithm developed using artificial intelligence that could be used by doctors to diagnose heart attacks more quickly and effectively.
In a panel discussion with executives at the 2024 BIO CEO conference this week in New York, the consensus emerged that artificial intelligence is here to stay, despite its occasional moments of hype, as its applications continually grow.
Biocom California’s Global Life Science Partnering & Investor Conference kicked off with a panel discussion focused on artificial intelligence (AI) in drug discovery. While there’s been a lot of hype over how AI and machine learning have the potential to help companies speed up drug development, panelists hypothesized the largest opportunities are in developing new capabilities, potentially increasing the success rate going from discovery to regulatory approval.
Baseimmune Ltd. has raised $11.3 million through a series A to accelerate the development of its deep learning AI technology for predicting future pathogen mutations to generate a series of longer-lasting, multistrain vaccines.
